LIVE: MTAP Deficiency and Deletion in Cancer


LIVE WEBINAR: June 4, 2026 | 12:00-1:00pm ET

Registration includes the live webinar link (sent via Zoom), the webinar recording, PDF of the slides, pre- and post- knowledge check questions, and continuing education credit (CME and CMLE).


This interactive live webinar is part 23 of the Emerging and Evolving Biomarkers Series

Description:

MTAP deficiency due to homozygous MTAP deletion at 9p21 is a new emerging biomarker shown to be associated with poor response to immunotherapy and predictive to MTA-cooperative PRMT5 inhibitors in different solid tumor types including non-small cell lung cancer. There is a need to define appropriate testing algorithms and standardize MTAP testing by immunohistochemistry for broad routine application.    

Learning Objectives:
  • Identify the biological consequences and the clinical impact of MTAP deficiency
  • Explain why MTAP deficiency is an emerging predictive biomarker
  • Explain the difference between MTAP deletion and MTAP deficiency
  • Evaluate the challenges of the methods used for analysis of MTAP status


Speaker:

Lukas Bubendorf, MD
University of Basel



Moderator:
Fei Dong, MD
Stanford University


Duration: 1 Hour
Level of Instruction: Intermediate
Live webinar: June 4, 2026 | 12:00pm ET

This program has been supported through an educational grant from Bristol-Myers Squibb.

How to Register:
  1. Click the "Register Now" Button
  2. Log in using your AMP credentials. If you do not have an AMP account, create a FREE account.
  3. Complete the "Demographic questionnaire for Emerging and Evolving Biomarkers Series" before the webinar date. You will only need to do this once for the entire series.

Continuing Education Credit Information

CME credit: 1.0
CMLE credit: 1.0 
Last day to claim credit: December 31, 2028

Accreditation Statements
AMA PRA Category 1 Credit(s)
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

CMLE
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Note: Join the AMP Family for discounted access to the most current educational resources!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation.